Anti-cancer drugs Biological activity In vitro study In vivo studies Synthesis method
ChemicalBook > CAS DataBase List > CO-1686

CO-1686

Anti-cancer drugs Biological activity In vitro study In vivo studies Synthesis method
CO-1686 Structure
CO-1686
  • CAS No.1374640-70-6
  • Chemical Name:CO-1686
  • CBNumber:CB22666396
  • Molecular Formula:C27H28F3N7O3
  • Formula Weight:555.55
  • MOL File:1374640-70-6.mol
CO-1686 Property
  • Density  :1.372±0.06 g/cm3(Predicted)
  • pka :13.23±0.70(Predicted)
  • CAS DataBase Reference :1374640-70-6
  • NCI Drug Dictionary :rociletinib
Safety
  • Risk Statements  :23-25-36
  • Safety Statements  :24
  • HS Code  :29335990
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal word
  • Hazard statements
  • Precautionary statements
CO-1686 Price More Price(3)
  • Brand: Cayman Chemical
  • Product number: 16244
  • Product name : CO-1686
  • Purity: ≥98%
  • Packaging: 1mg
  • Price: $55
  • Updated: 2021/03/22
  • Buy: Buy
  • Brand: Cayman Chemical
  • Product number: 16244
  • Product name : CO-1686
  • Purity: ≥98%
  • Packaging: 5mg
  • Price: $165
  • Updated: 2021/03/22
  • Buy: Buy
  • Brand: Cayman Chemical
  • Product number: 16244
  • Product name : CO-1686
  • Purity: ≥98%
  • Packaging: 10mg
  • Price: $275
  • Updated: 2021/03/22
  • Buy: Buy

CO-1686 Chemical Properties,Usage,Production

  • Anti-cancer drugs On May 20, 2014, Clovis Oncology announced that the US FDA had granted its test drug CO-1686 for breakthrough treatment drug qualification, as a second line, single administrated drug for the treatment of EFGR mutation non-small cell lung cancer (NSCLC) of the T790M mutation patients. The awarding for this breakthrough therapeutic drug eligibility was based on the efficacy and safety results of Co-1686 in an ongoing Phase 1/2 study. Data of related study have shown that CO-1686 is a third-generation EGFR inhibitor, being used for the treatment of non-small cell lung cancer, overcoming the drug resistance generated from the EGFR T790M mutations, and has excellent efficacy and tolerability on NSCLC with T790M + EGFR mutations. Its major market competitor, the third-generation EGFR inhibitor, AZD9291 (AstraZeneca) has also gained FDA's groundbreaking drug eligibility.
    CO-1686 is a novel, oral-administrated, targeted covalent (irreversible) inhibitor of the epidermal growth factor receptor (EGFR) mutations, being able to suppress key activation mutations and T790 drug-resistant mutations, leaving the wild-type EGFR signal unused. This drug was developed for the treatment of NSCLC patients carrying initially activated EGFR mutations and major resistant mutant T790M.
    The above information is compiled and edited by Xiao Nan of Chemicalbook.
  • Biological activity Rociletinib (CO-1686, AVL-301) is an irreversible, mutation-selective EGFR inhibitor that targets EGFRL858R/T790M and EGFRWT with a Ki of 21.5 nM and 303.3 nM, respectively. Phase 2.
    Target: EGFR (L858R/T790M) EGFR (wt)
    IC50: 21.5 nM (Ki) 303.3 nM (Ki)
  • In vitro study CO-1686 inhibited the p-EGFR in EGFR-expressing cells with an IC50 ranging from 62 to 187 nM while inhibiting EGFR phosphorylation. In three WT EGFR-expressing cells, the IC50 is larger than 2,000 nM. CO-1686 can selectively inhibit the growth of mutant EGFR expressing NSCLC cells with a GI50 ranging from 7 to 32 nM while inducing apoptosis. The CO-1686-resistant NSCLC cell line exhibited a signal for epithelial-mesenchymal transition and increased susceptibility to AKT inhibitors.
  • In vivo studies In all EGFR mutant models, as well as in transgenic mice expressing human EGFRL858R-and EGFRL858R/T790M, CO-1686 caused significant tumor growth inhibition in a dose-dependent manner.
  • Synthesis method 5-fluoro-2-nitroanisole was condensed with piperazine, acetylated and reduced to give 1-(3-methoxy-4-aminophenyl)-4-acetylpiperazine (4) In addition, use 2, 4-dichloro-5-trifluoro methyl pyrimidine to undergo condensation with 3-nitroaniline, reduction and amidation to obtain N-[3-(2-Chloro-5-trifluoromethyl-pyrimidin-4-amino) phenyl] acrylamide (7). 4 and 7 were condensed to give the EGFR inhibitor, the anticancer drug CO-1686 with a total yield of about 71% (based on 2, 4-dichloro-5-trifluoromethyl pyrimidine).
    Reference: Synthesis of CO-1686 [J]. Chinese Pharmaceutical Industry, 2014, 45 (8): 710-713.
    OF: (1) Lai Yisheng, male, professor, doctoral supervisor, engaged in anti-inflammatory and anti-tumor drugs studied. (2) Zhang Shan, female, graduate students, professional direction: medicinal chemistry.
CO-1686 Preparation Products And Raw materials
Raw materials
Preparation Products
Global(170)Suppliers
  • Supplier:
    Henan Tianfu Chemical Co.,Ltd.
  • Tel:0371-55170693
  • Fax:0371-55170693
  • Email:info@tianfuchem.com
  • Country:CHINA
  • ProdList:22607
  • Advantage:55
  • Supplier:
    Shanghai Yingrui Biopharma Co., Ltd.
  • Tel:+86-21-33585366 E-mail:sales03@shyrchem.com
  • Fax:+86-21-34979012
  • Email:sales03@shyrchem.com
  • Country:CHINA
  • ProdList:739
  • Advantage:60
  • Supplier:
    ATK CHEMICAL COMPANY LIMITED
  • Tel:+86 21 5161 9050/ 5187 7795
  • Fax:+86 21 5161 9052/ 5187 7796
  • Email:ivan@atkchemical.com
  • Country:CHINA
  • ProdList:26734
  • Advantage:60
  • Supplier:
    career henan chemical co
  • Tel:+86-371-86658258
  • Fax:
  • Email:sales@coreychem.com
  • Country:CHINA
  • ProdList:29961
  • Advantage:58
  • Supplier:
    Biochempartner
  • Tel:0086-13720134139
  • Fax:
  • Email:candy@biochempartner.com
  • Country:CHINA
  • ProdList:968
  • Advantage:58
  • Supplier:
    BOC Sciences
  • Tel:1-631-485-4226
  • Fax:1-631-614-7828
  • Email:inquiry@bocsci.com
  • Country:United States
  • ProdList:19753
  • Advantage:58
  • Supplier:
    Chongqing Chemdad Co., Ltd
  • Tel:+86-13650506873
  • Fax:
  • Email:sales@chemdad.com
  • Country:CHINA
  • ProdList:37282
  • Advantage:58
1374640-70-6, CO-1686Related Search:
  • CO-1686
  • AVL-301
  • CNX-419
  • CO-1686 (AVL-301)
  • CO-1686/CO1686
  • N-[3-[[2-[[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide
  • Clovis CO-1686
  • CO-1686(free base)
  • CO1686; CO-1686; CO 1686; AVL301; AVL 301; AVL-301; CNX419; CNX 419; CNX-419; ROCILETINIB.
  • Rociletinib(AVL-301,CNX-419,CO-1686)
  • N-(3-(2-(4-(4-acetylpiperazin-1-yl)-2-methoxyphenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)phenyl)acrylamide
  • CO-1686, >=98%
  • N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide
  • Rociletinib (CO1686,CNX419)
  • ROCILETINIB
  • Rociletinib(CO1686)
  • 2-Propenamide, N-[3-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-
  • Rociletinib (CO-1686, AVL-301)
  • Co 1686 N-[3-[[2-[[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide
  • N-[3-[[2-[[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide Co 1686
  • CO-1686(ROCILETINIB)
  • Pyridostadin
  • N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl
  • CS-851
  • ROCILETINIB; AVL-301; CNX-419;CO 1686;CO1686
  • N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide
  • CO-1686 (Rociletinib, AVL-301)
  • Pyridostadin 3TFA
  • CO-1686 USP/EP/BP
  • 1374640-70-6
  • C27H28F3N7O3
  • Inhibitors
  • API